Surveys were implemented in selected countries, including Jamaica, Malaysia, Nepal, and Cte dIvoire
Notable innovations include: SGLT2 inhibitors improving both glycemic control and kidney health
Same active ingredient, same dose, different delivery system
Although the detrimental effect of GLP-1 agonists have remained unclear with suggestions of increased risk of some cancers, recent reports in fact suggest a reduced risk of colorectal cancer (CRC)
Limited 28-day oral gavage studies in rats at doses up to 100 mg/kg/day show no obvious adverse clinical signs, body weight changes, or gross organ pathology upon autopsy (Pullaiah et al
These can range from mild to moderate and often improve as your body adjusts to the medication, especially if the dosage is increased gradually